Sargent Bickham Lagudis’s Axsome Therapeutics AXSM Stock Holding History

Sargent Bickham Lagudis’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$17K	Hold	220	–	–	﹤0.01%	638
2022 Q3	$10K	Hold	220	–	–	﹤0.01%	685
2022 Q2	$8K	Hold	220	–	–	﹤0.01%	722
2022 Q1	$9K	Hold	220	–	–	﹤0.01%	720
2021 Q4	$8K	Hold	220	–	–	﹤0.01%	737
2021 Q3	$7K	Sell	220 -145	-40%	-$5.65K	﹤0.01%	761
2021 Q2	$25K	Hold	365	–	–	﹤0.01%	571
2021 Q1	$21K	Hold	365	–	–	﹤0.01%	576
2020 Q4	$30K	Hold	365	–	–	﹤0.01%	492
2020 Q3	$26K	Hold	365	–	–	﹤0.01%	466
2020 Q2	$30K	Hold	365	–	–	﹤0.01%	430
2020 Q1	$21K	Hold	365	–	–	﹤0.01%	462
2019 Q4	$38K	Buy	365 +145	+66%	+$5.86K	﹤0.01%	425
2019 Q3	$4K	Hold	220	–	–	﹤0.01%	636
2019 Q2	$6K	Buy	+220	New	+$4.41K	﹤0.01%	639

Other funds holding AXSM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

ACM

Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Sargent Bickham Lagudis's AXSM Position: Q4 2022 in Review

Sargent Bickham Lagudis held its Axsome Therapeutics (AXSM) position steady in Q4 2022 at 220 shares worth $17K. The position accounts for ﹤0.01% of the portfolio, ranked #638.

Sargent Bickham Lagudis first reported a position in AXSM in Q2 2019 and has held it in 15 quarters since. The position peaked at $38K in Q4 2019. 219 funds tracked by Wall St. Rank hold AXSM as of Q4 2022.

Sargent Bickham Lagudis held 220 shares of Axsome Therapeutics worth $17K as of Q4 2022.
Sargent Bickham Lagudis left its Axsome Therapeutics share count unchanged in Q4 2022.
Axsome Therapeutics made up ﹤0.01% of Sargent Bickham Lagudis's portfolio in Q4 2022, its #638 holding.
Sargent Bickham Lagudis first reported a position in Axsome Therapeutics in Q2 2019 and has held it in 15 quarters since.
Sargent Bickham Lagudis's Axsome Therapeutics position peaked at $38K in Q4 2019.
219 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q4 2022.

Based on Sargent Bickham Lagudis's 13F filing for Q4 2022, filed 23 Jan 2023.